Psychedelic microdose for emotional distress in advanced illness
Treatments studied
Part of Mental health clinical trials.
This trial tests whether very low doses of psilocybin (a psychedelic substance) can help reduce emotional distress in people with a life-limiting illness. If you are receiving palliative care and feeling anxious or depressed, this study might offer a way to explore a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced illness and are under palliative care, with a life expectancy of 2 to 12 months.
- You are experiencing emotional or psychological distress, like anxiety or depression.
- You live in the community or in a chronic care facility where a family member can give you the study medication.
- You and your family members have no history of psychotic or bipolar disorder.
- You have not taken high-dose psychedelics in the past year.
- You are able to understand English or French and can complete the study assessments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called psilocybin, combined with supportive talk therapy, can help reduce feelings of hopelessness and loss of meaning in people with advanced cancer. If it works, it could offer a new way to improve emotional well-being during a difficult time.
This Phase 2 study tests how LSD may affect comfort and quality of life for people with advanced or end-stage life-limiting illness. It also checks whether the medicine is safe and can be given in a controlled way in palliative care settings.
This trial tests whether psilocybin-assisted therapy can help caregivers of people with advanced cancer who feel anxious or depressed. It focuses on improving emotional well-being and relationships.
This study tests whether a therapy combining psilocybin (a psychedelic substance) with counseling can help improve emotional well-being in people with advanced cancer who have symptoms of depression. It aims to see if this approach can ease suffering and improve quality of life.
This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.
This Phase 2 study tests whether psilocybin therapy can reduce deep distress (“demoralization”) in people receiving palliative (comfort-focused) care. It may help with mood and well-being, but you must meet safety and medication requirements to join.
Hear when a new Psychological Distress trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.